SRS16-86 is a third generation ferrostatin derivative with greater metabolic and plasma stability for in vivo studies. It protected mice in a renal severe ischemia-reperfusion injury model via inhibition of ferroptosis.1 SRS16-86 enhanced functional recovery after spinal cord injury in a rat model via upregulation of GPX4, GSH, and xCT as well as downregulation of lipid peroxidation marker 4-hydroxynonenal.2
